Summary by Moomoo AI
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) HELD ITS 49TH BOARD MEETING ON 29 APRIL 2024, ATTENDED BY ALL 12 DIRECTORS. The Conference approved the 2024 First Quarter Report and agreed to provide a loan of no more than $6700 million equivalent to its joint venture, Fosun Cait Biotechnology Co., Ltd. The meeting was hosted by Mr. Wu Yifang, the Executive Director and Chairman, and complied with relevant legal and regulatory requirements. The Borrowing Bill for the Resolution of the Meeting is subject to approval by the General Meeting and constitutes a related transaction as a member of the Board of Directors is a former or current director of Star Kate. The relevant directors abstained at the time of the vote and the motion was approved before the independent non-executive directors.